Navigation Links
Rochester Medical Announces New Opportunity in the United Kingdom
Date:9/21/2009

STEWARTVILLE, Minn., Sept. 21 /PRNewswire-FirstCall/ -- Rochester Medical Corporation (Nasdaq: ROCM) today announced that the Company's FemSoft(R) Insert has been approved for inclusion in Part IX of the UK Drug Tariff as a prescription product which is reimbursable.

There are no other products listed in the Drug Tariff specifically for managing female stress urinary incontinence, and the Company believes that for many women this will be a very welcome addition that offers a discreet, non-surgical, odor-free, secure, and safe alternative to absorbents.

FemSoft(R) Inserts are particularly effective in situations where leakage occurs during certain physical activities such as exercise, coughing, laughing, or sneezing.

Hugh McLeod, General Manager of the U.K. business commented that this represents a significant opportunity for Rochester Medical and will enhance the Company's position as the leading worldwide innovator and marketer of silicone continence care devices.

He noted that the FemSoft(R) Insert product line fits perfectly alongside Rochester Medical's current portfolio of catheters for intermittent self-catheterization and will be marketed through the same customer base of Urology Nurse Specialists and Continence Nurse Specialists.

Commenting on the news, Anthony J. Conway Rochester Medical CEO and President said, "This is excellent news for women in the United Kingdom and also great news for Rochester Medical. We believe the FemSoft(R) Insert provides an elegant non-surgical, comfortable, and dry alternative to absorbents. Earlier this year we announced that U.S. Medicare has given preliminary reimbursement approval to the FemSoft Insert, and we expect final confirmation in the near future. In both the U.K. and U.S. we expect implementation of the reimbursement to begin in January 2010, and we are making sales and marketing preparations accordingly."

About Rochester Medical

Rochester Medical is the world's leading manufacturer of all-silicone catheters for urological and continence care applications. Our advanced line of latex-free products features male external catheters, intermittent catheters, Foley catheters and urethral inserts as well as latex-free accessories.

More information about Rochester Medical is available on its website at http://www.rocm.com.

Forward-Looking Statement

This press release contains "forward-looking statements" that are based on currently available information, operating plans and management's expectations about future events and trends. They inherently involve risks and uncertainties that could cause actual results to differ materially from those predicted in such forward-looking statements, including the uncertainty of estimated revenues and profits, the uncertainty of current domestic and international economic conditions that could adversely affect the level of demand for the Company's products and increased volatility in foreign exchange rates, the uncertainty of market acceptance of new product introductions, the uncertainty of gaining new strategic relationships or locating and capitalizing on strategic opportunities, the uncertainty of timing of private label sales revenues (particularly international customers), FDA and other regulatory review and response times, and other risk factors listed from time to time in the Company's SEC reports and filings, including, without limitation, the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended September 30, 2008 and subsequent reports on Forms 10-Q and 8-K. Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact: Anthony J. Conway
    President and Chief Executive Officer
    Rochester Medical Corporation
    Phone: (507) 533-9600


'/>"/>
SOURCE Rochester Medical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rochester Medical Launches StrataSI(TM) & StrataNF(TM) Next Generation Foley Catheters
2. Rochester Medical Reports Third Quarter Results
3. Rochester Medical Announces Third Quarter 2009 Earnings Conference Call July 30, 2009
4. Purple Communications Dream Bigger Initiative Honors Rochester Physician and Deaf Community Trailblazer
5. Rochester Medical Corporation Set to Join Russell 3000 Index
6. Rochester Medical Reports Second Quarter Results
7. Rochester Medical Announces Second Quarter 2009 Earnings Conference Call April 30, 2009
8. Rochester Medical Renews Share Repurchase Activity
9. University of Rochester Launches iTraining for Emergency Responders
10. Rochester Medical Reports First Quarter Results
11. Rochester study raises new questions about controversial plastics chemical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology: